Foreign biotech firms likely to rush into Kosdaq market The KRX began to allow foreign companies to use the technology exception rule this year
Translated by Kim So-in 공개 2019-12-11 08:00:00
이 기사는 2019년 12월 11일 08:00 thebell 에 표출된 기사입니다.
The 2019 is the first year that the Korea Exchange (KRX) opened the door of secondary Kosdaq market to foreign biotech companies, revising Kosdaq listing requirements. Foreign biotech companies who have prepared to be listed on the Korean market are expected to rush into the market from next year.◇ KRX allows foreign companies to use the technology exception rule
The KRX began to allow foreign companies to benefit from the technology exception rule to go public on the secondary Kosdaq market as of July 1, on the condition that they undergo stricter reviews on technological competitiveness.
The KRX revised the policy as foreign biotech companies who are willing to be listed on the Kosdaq market have increased continuously. These companies chose to go public on the Korean market, tempted by the Kosdaq bio sector’s strong valuations. Before the revision, foreign biotech companies had to go public through other special tracks, such as ‘Tesla standard.’
U.S.-based Psomagen is likely to be the first overseas biotech company to be listed on the secondary bourse Kosdaq under the technology exception policy. Through the Kosdaq listing, Psomagen aims to broaden its share in the direct-to-consumer (DTC) genetic testing and microbiome market. The firm submitted a preliminary review application to the KRX last month and is waiting for the approval.
Foreign biotech firms are queuing up to list on the Kosdaq bourse after Psomagen. NeoImmuneTech (U.S.), Prestige Biopharma (Singapore), Avelliono Lab (U.S.) and Contera Pharma (Denmark) will follow suit. They all hired domestic securities firms as lead managers for their IPO and are working to be listed under the technology exception rule. The IPO of NeoImmuneTech and Prestige Biopharma are expected to be around one trillion won in size.
◇ Foreign companies’ IPOs are considered a half success
Most of foreign biotech companies that plan to be listed on the Kosdaq market are related to South Korea directly or indirectly. Psomagen is a U.S. subsidiary of Kosdaq-listed Macrogen. NeoImmuneTech is co-developing Hyleukin-7 with Korean company Genexine. Singapore-based Prestige Biopharma’s owner and key developers are Koreans.
Considering such IPOs are not done by ‘pure’ foreign companies, their listings on the Kosdaq are considered a half success. However, if their listings on the Kosdaq using the technology exception rule hit the jackpot, pure foreign biotech firms may shift eyes toward the Kosdaq market.
Up until now, Cognate BioServices and PeproMene Bio are two of the very few pure foreign firms that have signed contracts with domestic brokerages for their IPOs. But there is room for the Kosdaq bourse to become the main pillar in the global biotech market, depending on future IPO results.
Accordingly, securities firms’ investment banking (IB) divisions are recently focusing on foreign biotech firms that have little connection with Korea. Domestic companies that have built their networks with foreign affiliates are now approaching actively to pure foreign biotech companies. Those who are in charge of biotech firms’ IPOs visited overseas markets very often this year.
Their main targets are foreign biotech companies that domestic venture capital firms have already invested in. Despite no direct connection with Korea, the foreign biotech companies have high understanding of Korean capital markets.
◇ The KRX raised technological hurdles
The KRX began to allow foreign companies to use the technology exception rule on the condition that they undergo stricter reviews on technological competitiveness. Foreign firms must receive 'A' rating from all two rating agencies designated by the KRX. Korean companies must receive ‘A’ and higher than ‘BBB’ rating from two rating agencies designated by the KRX. It is burdensome that receiving a good rating in the technology assessment is getting more difficult lately.
Despite higher hurdles, foreign biotech firms are expected to keep tapping the Kosdaq market. Lower listing expenses and the higher premiums are among the other attractions of the Kosdaq market.
(By reporter Yang Jung-woo)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 우리금융 "롯데손보 M&A, 과도한 가격 부담 안한다"
- 신한캐피탈, 지속성장 포트폴리오 리밸런싱 체계 강화
- 하나금융, ELS 악재에도 실적 선방…확고한 수익 기반
- 하나금융, 자본비율 하락에도 주주환원 강화 의지
- 국민연금, '역대 최대 1.5조' 출자사업 닻 올렸다
- [도전 직면한 하이브 멀티레이블]하이브, 강한 자율성 보장 '양날의 검' 됐나
- [퍼포먼스&스톡]꺾여버린 기세에…포스코홀딩스, '자사주 소각' 카드 재소환
- [퍼포먼스&스톡]LG엔솔 예견된 실적·주가 하락, 비용 절감 '집중'
- [퍼포먼스&스톡]포스코인터, 컨센서스 웃돌았지만 주가는 '주춤'
- 신한금융, ‘리딩금융’ 재탈환에 주주환원 강화 자신감